In case you missed it, it’s worth looking at this memo that the big anti-abortion group Susan B. Anthony Pro-Life America sent to Republican lawmakers last week outlining messaging points and policy proposals for the party to push in the wake of Roe’s demise.
The messaging tight-rope they’re walking to avoid fully dancing on Roe’s grave remains interesting.Read More
For weeks we’ve been watching Republicans squirm to find a messaging balance.
The party as a whole is attempting to walk a bizarre tightrope as leaders try to downplay Republicans’ unadulterated joy at the defeat of Roe, a social issue the GOP’s been using as a policy placeholder for decades, in the face of our evidence-backed reality: support for abortion access is at a record high among Americans across the political spectrum.Read More
He should’ve known.
As we know, Virginia’s new Republican Gov. Glenn Youngkin is working furiously to make good on his campaign promise to essentially make combatting Republican grievances, real and imagined, the top priority of the Virginia state government. We wrote recently about his reversal of the state’s universal masking policy for schools. He also moved to ban the teaching of “inherently divisive concepts” (read: “Critical Race Theory”) in public schools on Day One.
During an interview with conservative radio host John Fredericks earlier this week, Youngkin announced a new tip line his administration had set up, asking parents to notify the state government with reports of public teachers “behaving objectionably,” aka talking about race and systemic racism in the classroom, concepts that the GOP continues to squeeze beneath the ill-suited label “Critical Race Theory” — an academic framework that’s ruffled the right into hysterics in recent months.Read More
But some Republicans are already using the Biden administration’s new, common sense decision to pour gasoline on their baseless federal overreach fights.
The Food and Drug Administration removed two monoclonal antibody therapies from its list of approved treatments for COVID-19 this week, at least temporarily. Citing clinical data, the FDA said in a statement that it has found two of the treatments “are highly unlikely to be active against the omicron variant, which is circulating at a very high frequency throughout the United States.” HHS sent out a letter to state officials this week, alerting them that the federal government would stop handing out the treatments made by Regeneron Pharmaceuticals and Eli Lilly to states for now, according to the Washington Post which obtained a copy of the letter.Read More